Psoriasis, Psychotropic Drugs and Psychiatric Comorbidities: A Case-Control Study with Inpatients
Introduction: Psoriasis is a chronic inflammatory dermatosis with significant impact on quality of life and multiple comorbidities, with recognition especially given to cardiovascular risk factors. Recently it has been highlighted the high prevalence of psychiatric comorbidities.
Methods: The primary outcome was to assess the prevalence of psychotropic drugs in the chronic medication of patients with diagnosis of psoriasis. We performed a case-control study at the Department of Dermatology of Coimbra Hospital and University Centre, between 2010 and 2015. The results were compared with age- and gender-matched controls. The medication was grouped according to the INFARMED. The secondary outcome was to compare the prevalence of treatments for cardiovascular risk factors in both groups and to compile the information on psychiatric comorbidities available in the medical records of the psoriasis patients included in this study. The data were processed by STATA 14 and statistical significance was considered when p<0.05. Results: The sample consisted of 79 patients, 67% male and 33% female, mean age of 59.30±17.17 years. There was association (p<0.01) between psoriasis and psychotropic drugs, especially anxiolytics and antipsychotics, with 63% of patients with at least one psychotropic drug. It was found an association between psoriasis and antihypertensive drugs (p<0.05). Frequently, psychiatric diagnoses were not mentioned or were inaccurately described in the medical records.
Conclusion: The results highlight the high prevalence of psychotropic drugs and reinforce previous studies about the lack of assessment of psychopathology in dermatology, a topic of high relevance in patients with psychodermatologic diseases, such as psoriasis.
Coimbra S, Oliveira H, Figueiredo A, Rocha-Pereira P,
Santos-Silva A. Factors associated with the length of remission
of psoriasis vulgaris. Clin Drug Investig. 2013;
Ferreira BI, Abreu JL, Reis JP, Figueiredo AM. Psoriasis
and associated psychiatric disorders: a systematic review
on etiopathogenesis and clinical correlation. J Clin Aesthet
Dermatol. 2016; 9:36-43.
Hunter HJ, Griffiths CE, Kleyn CE. Does psychosocial
stress play a role in the exacerbation of psoriasis? Br J
Dermatol. 2013; 169:965-74.
Kumar S, Kachhawha D, Das Koolwal G, Gehlot S, Awasthi
A. Psychiatric morbidity in psoriasis patients: a pilot
study. Indian J Dermatol Venereol Leprol. 2011; 77:625.
Heller MM, Lee ES, Koo JY. Stress as an influencing factor
in psoriasis. Skin Therapy Lett. 2011; 16:1-4.
Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB,
Augustin M. Psoriasis: is the impairment to a patient's
life cumulative? J Eur Acad Dermatol Venereol. 2010;
Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin
DM. Psoriasis causes as much disability as other
major medical diseases. J Am Acad Dermatol. 1999;
American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders.5th ed. Arlington: APA;
Chamoun A, Goudetsidis L, Poot F, Bourdeaud'hui F, Titeca
G. Psoriasis et depression. Rev Med Brux. 2015;
Fleming P, Bai JW, Pratt M, Sibbald C, Lynde C, Gulliver
WP. The prevalence of anxiety in patients with psoriasis:
a systematic review of observational studies and clinical
trials. J Eur Acad Dermatol Venereol. 2016 (in press).
Evers AW, Verhoeven EW, Kraaimaat FW, de Jong EM, de
Brouwer SJ, Schalkwijk J, et al. How stress gets under the
skin: cortisol and stress reactivity in psoriasis. Br J Dermatol.
Mizara A, Papadopoulos L, McBride SR. Core beliefs
and psychological distress in patients with psoriasis
and atopic eczema attending secondary care: the role
of schemas in chronic skin disease. Br J Dermatol. 2012;
Torres-Hernández M, López-García S, Pedroza-Escobar
D, Escamilla-Tilch M. The role of alexithymia as a psychosomatic
factor in psoriasis. Rev Med Inst Mex Seguro Soc.
Naldi L, Parazzini F, Brevi A, Peserico A, Veller Fornasa C,
Grosso G, et al. Family history, smoking habits, alcohol
consumption and risk of psoriasis. Br J Dermatol. 1992;
McAleer MA, Mason DL, Cunningham S, O'Shea SJ, Mc-
Cormick PA, Stone C, et al. Alcohol misuse in patients
with psoriasis: identification and relationship to disease
severity and psychologicaldistress. Br J Dermatol. 2011;
Kim N, Thrash B, Menter A. Comorbidities in psoriasis
patients. Semin Cutan Med Surg. 2010; 29:10-5.
Bouguéon K, Misery L. Depression and psoriasis. Ann
Dermatol Venereol. 2008; 135 (Suppl 4):S254-8.
Shutty BG, West C, Huang KE, Landis E, Dabade T, Browder
B, et al. Sleep disturbances in psoriasis. Dermatol
Online J. 2013; 19:1.
Sampogna F, Gisondi P, Tabolli S, Abeni D; IDI Multipurpose
Psoriasis Research on Vital Experiences investigators.
Impairment of sexual life in patients with psoriasis.
Dermatology. 2007; 214:144-50.
Cabete J, Torres T, Vilarinho T, Ferreira A, Selores M.
Erectile dysfunction in psoriasis patients. Eur J Dermatol.
Moon HS, Mizara A, McBride SR. Psoriasis and psycho-
-dermatology. Dermatol Ther. 2013; 3:117-30.
Jafferany M, Franca K. Psychodermatology: basics concepts.
Acta Derm Venereol. 2016; 96:35-7.
All articles in this journal are Open Access under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).